Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18403201 | 0.80 | CYP1A2 (0.42) | PDK2PDK4KMT2AMEN1PGR | |
| SCHEMBL2270532 | 0.78 | PDK2 (0.53) | PDK2PDK4KMT2APGRMAPT | |
| SCHEMBL24112426 | 0.78 | PDK2 (0.53) | PDK2PDK4PGRDRD1HTR6 | |
| SCHEMBL30484130 | 0.76 | PDK2 (0.52) | PDK2PDK4PGRTP53HTR6 | |
| SCHEMBL31381642 | 0.76 | PDK2 (0.52) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL3865185 | 0.76 | PDK2 (0.52) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL3149249 | 0.76 | PDK2 (0.52) | PDK2PDK4PGRTP53HTR6 | |
| SCHEMBL3485352 | 0.74 | KMT2A (0.47) | PDK2PDK4KMT2AMEN1PGR | |
| SCHEMBL9676842 | 0.74 | PDK2 (0.56) | PDK2PDK4PGRLMNADRD1 | |
| SCHEMBL9591821 | 0.73 | PDK2 (0.71) | PDK2PDK4KMT2AMEN1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| CN-1984892-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7122680-B2 | 3-Substituted oxindole β3 agonsists | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1341759-B1 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| US-6825220-B2 | INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ELI LILLY AND COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0653426-B1 | Indole derivatives, salts thereof and heart affection therapeutic agent comprising the same | KOWA CO (JP) | 1998-07-22 | — | — | EP | disclosed |
| US-5510366-A | INOTROPIC, ANTIARRHYMTHMIA AGENTS, VASODILATORS | KOWA CO., LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0653426-A1 | Indole derivatives, salts thereof and heart affection therapeutic agent comprising the same | KOWA COMPANY, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-4622336-A | ANALGESICS | SANDOZ LTD. (CH) | 1986-11-11 | — | — | US | disclosed |
| WO-1983002610-A1 | DERIVATIVES OF 3,3-DIALKYL-INDOLIN AND OF 3,3-ALKYLENE-INDOLIN, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1983-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | PDK2 1902/4885PDK4 2747/4885KMT2A 4568/4885 |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | PDK2 517/4885PDK4 901/4885KMT2A 3728/4885 |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ADRB3, ADRB2, ADRB1 | PDK2 2277/4885PDK4 2822/4885KMT2A 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.